<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483119</url>
  </required_header>
  <id_info>
    <org_study_id>3343</org_study_id>
    <nct_id>NCT00483119</nct_id>
  </id_info>
  <brief_title>Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus</brief_title>
  <official_title>Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two standard treatments for pemphigus to determine
      which more effectively improves the clinical manifestations of the disease and decreases
      serum level of the autoantibodies which cause the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pemphigus is a serious and life-threatening autoimmune disease characterized by blisters and
      erosions that occur on the skin and oral mucosa. It is caused by autoantibodies that attack
      desmoglein 1 and 3, adhesion molecules that are present on the surface of the cells
      (keratinocytes) that make up the superficial layer of the skin. As a result these cells stop
      sticking together, and come apart resulting in the formation of blisters on the skin.

      Pemphigus is usually treated with systemic corticosteroids often given together with
      immunosuppressive drugs such as Cytoxan (cyclophosphamide), Imuran (azathioprine),
      methotrexate, CellCept (mycophenolate mofetil) and others. However, the prolonged and high
      doses of systemic steroids and other immunosuppressive agents used to treat the disease are
      associated with significant toxicity.

      A new treatment which is now being used to treat pemphigus patients that are unresponsive, or
      that have developed complications to conventional treatment is IVIg (intravenous
      immunoglobulin). IVIg consists of one of the protein fractions present in blood. It is the
      fraction that contains antibodies and is called immunoglobulin (Ig). It is purified from
      blood that has been collected from thousands of donors and treated to remove potential
      infectious agents. It is administered intravenously (IV) over several hours, several days in
      succession. The cycles are usually repeated every 2 to 4 weeks until the disease is
      controlled.

      IVIg treatment is currently given in either of two ways, either by itself or with an
      immunosuppressive drug such as cyclophosphamide or azathioprine. It is unknown which of these
      two procedures is better. This trial is being conducted to determine which treatment is more
      effective.

      The trial is being conducted in patients with pemphigus that are not responding to, or have
      developed complications from, standard treatment. All patients will be treated with IVIg
      administered using a standard protocol. The IVIg will be given daily for 4 days, and this
      cycle will be repeated every other week for a total of 4 cycles. In addition, half of the
      patients will be selected by chance to also be treated with cyclophosphamide, an
      immunosuppressive drug often used to treat other autoimmune diseases including pemphigus. The
      cyclophosphamide is a pill that is taken 3 times a day. A total of 12 patients will be
      treated in each arm of the trial. The trial is being conducted by Dr. Jean-Claude Bystryn at
      the New York University Medical Center.

      The extent and activity of the disease, as well as the blood levels of pemphigus antibodies,
      will be measured at baseline prior to entry into the trial and periodically during the trial.

      The goal of the study is to determine whether there is a difference between the two
      treatments in the rate at which: 1) the activity and extent of the disease improves, 2) the
      dose of corticosteroids required to treat the disease can be reduced, and 3) the blood level
      of pemphigus antibodies decrease.

      This trial will test this hypothesis by examining whether IVIg treatment given with
      cyclophosphamide results in a more rapid decline in circulating pemphigus antibodies than
      when given alone.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to the death of the PI.
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Outcome: Extent and Severity of Disease</measure>
    <time_frame>6 - 10 weeks after initiation of therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levels of Pemphigus Antibodies</measure>
    <time_frame>6-10 weeks after initiation of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of Treatment: Measured in Renal Toxicity, Myelosuppression or Hepatic Toxicity</measure>
    <time_frame>Throughout course of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to be Weaned Off Steroids</measure>
    <time_frame>Measured 6 and 10 weeks after initiation of IVIg treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Pemphigus Vulgaris</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IVIg alone (intravenous immunoglobulin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IVIg with cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous immunoglobulin</intervention_name>
    <description>Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>IVIg</other_name>
    <other_name>Gamunex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>CP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lesions consistent with pemphigus foliaceus or vulgaris

          -  Diagnosis confirmed by histology and IIF ≥ 40 within past month

          -  On ≥20mg/day of prednisone per day for two weeks or ≥ 80mg/day for one week

          -  Women of childbearing potential negative HCG obtained two weeks prior to first IVIg

          -  Agrees to two acceptable forms of contraception* if randomized to cyclophosphamide
             group:

          -  IUD (except progesterone T), Combination oral contraceptives, transdermal patch,
             vaginal ring, hormonal injectables or implantables, male latex condom, diaphragm,
             cervical cap, or vaginal sponge (contains spermicide)

          -  Normal organ function confirmed by CBC, UA, LFTs and Ig levels within defined
             inclusion criteria

          -  Responds yes to at least one of the criteria below:

          -  Persistence of clinical manifestations of disease despite steroid treatment

          -  Flare in disease activity after an attempt at steroid tapering

          -  Failure of established lesions to heal

          -  Rapidly progressive disease.

          -  Conventional therapy is relatively contraindicated i.e. side effects, co-morbid
             conditions

          -  systemic infections, peptic ulcers, osteoporosis, hypertension, cataracts or others

        Exclusion Criteria:

          -  Use of IVIg within past 3 weeks or the use of a cytotoxic drug within the past 2 weeks

          -  Participating in another clinical trial at the time of screening and enrollment

          -  Medical condition that precludes use of IVIg or cyclophosphamide (i.e. pregnancy
             breastfeeding, underlying chronic infection, concurrent opportunistic infection,
             sepsis or volume depletion

          -  Renal insufficiency ( GFR &lt;90, proteinuria (&gt;1+, x 2), creatinine &gt;1.8 or increased
             WBC or RBCs which cannot be explained by cystitis.)

          -  Known hypersensitivity to study drugs, IVIg or cyclophosphamide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude Bystryn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU MEDICAL CENTER</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Green MG, Bystryn JC. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol. 2008 Dec;144(12):1621-4. doi: 10.1001/archdermatol.2008.503.</citation>
    <PMID>19075146</PMID>
  </reference>
  <reference>
    <citation>Czernik A, Bystryn JC. Kinetics of response to conventional treatment in patients with pemphigus vulgaris. Arch Dermatol. 2008 May;144(5):682-3. doi: 10.1001/archderm.144.5.682.</citation>
    <PMID>18490602</PMID>
  </reference>
  <reference>
    <citation>Czernik A, Beutner EH, Bystryn JC. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol. 2008 May;58(5):796-801. doi: 10.1016/j.jaad.2008.01.007.</citation>
    <PMID>18423257</PMID>
  </reference>
  <reference>
    <citation>Czernik A, Bystryn JC. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. Arch Dermatol. 2008 May;144(5):658-61. doi: 10.1001/archderm.144.5.658.</citation>
    <PMID>18490594</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2007</study_first_submitted>
  <study_first_submitted_qc>June 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2007</study_first_posted>
  <results_first_submitted>October 5, 2015</results_first_submitted>
  <results_first_submitted_qc>January 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 18, 2016</results_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pemphigus vulgaris</keyword>
  <keyword>IVIg</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>treatment</keyword>
  <keyword>pemphigus antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IVIg Alone</title>
          <description>IVIg alone
intravenous immunoglobulin: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles</description>
        </group>
        <group group_id="P2">
          <title>IVIg With Cyclophosphamide</title>
          <description>IVIg with cyclophosphamide
cyclophosphamide: cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This number is based only on the number of patients who passed screening and then were enrolled. Please note that this study was not evaluable due to the untimely death of the study Principal Investigator as noted previously.</population>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>IVIg alone
intravenous immunoglobulin: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>IVIg with cyclophosphamide
cyclophosphamide: cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.2" lower_limit="45" upper_limit="68"/>
                    <measurement group_id="B2" value="56.25" lower_limit="47" upper_limit="66"/>
                    <measurement group_id="B3" value="59" lower_limit="45" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Outcome: Extent and Severity of Disease</title>
        <time_frame>6 - 10 weeks after initiation of therapy</time_frame>
        <population>Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>IVIg Alone</title>
            <description>IVIg alone
intravenous immunoglobulin: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles</description>
          </group>
          <group group_id="O2">
            <title>IVIg With Cyclophosphamide</title>
            <description>IVIg with cyclophosphamide
cyclophosphamide: cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcome: Extent and Severity of Disease</title>
          <population>Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Levels of Pemphigus Antibodies</title>
        <time_frame>6-10 weeks after initiation of therapy</time_frame>
        <population>Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>IVIg Alone</title>
            <description>IVIg alone
intravenous immunoglobulin: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles</description>
          </group>
          <group group_id="O2">
            <title>IVIg With Cyclophosphamide</title>
            <description>IVIg with cyclophosphamide
cyclophosphamide: cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Pemphigus Antibodies</title>
          <population>Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity of Treatment: Measured in Renal Toxicity, Myelosuppression or Hepatic Toxicity</title>
        <time_frame>Throughout course of study</time_frame>
        <population>Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>IVIg Alone</title>
            <description>IVIg alone
intravenous immunoglobulin: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles</description>
          </group>
          <group group_id="O2">
            <title>IVIg With Cyclophosphamide</title>
            <description>IVIg with cyclophosphamide
cyclophosphamide: cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity of Treatment: Measured in Renal Toxicity, Myelosuppression or Hepatic Toxicity</title>
          <population>Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ability to be Weaned Off Steroids</title>
        <time_frame>Measured 6 and 10 weeks after initiation of IVIg treatment</time_frame>
        <population>Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>IVIg Alone</title>
            <description>IVIg alone
intravenous immunoglobulin: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles</description>
          </group>
          <group group_id="O2">
            <title>IVIg With Cyclophosphamide</title>
            <description>IVIg with cyclophosphamide
cyclophosphamide: cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Ability to be Weaned Off Steroids</title>
          <population>Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>IVIg alone
intravenous immunoglobulin: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>IVIg with cyclophosphamide
cyclophosphamide: cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation not considered related to treatment</sub_title>
                <description>event occurred 5 days post infusion</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Elevated blood pressure; blurred vision, nausea and tearing</sub_title>
                <description>Day 3 of IVIG infusion cycle 3; At the infusion suite his blood pressure was 160/106 mmHg and the headache was still persistent. IVIG was not infused. Patient was sent to NYULMC ER for evaluation. Brain CT was normal. Patient withdrawn from study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Tightness</sub_title>
                <description>Intermittant following infusion for 2 hours</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral Candida Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Muscle Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vasovega</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Creatine Levels</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Elevated Urine Protein Levels</sub_title>
                <description>Creatine levels remained normal throughout event.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmanary Adema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Localized minor inflammation</sub_title>
                <description>At infusion site.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mild skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Penile Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elise Kelman, Associate Director of Research Administration</name_or_title>
      <organization>NYU School of Medicine</organization>
      <phone>2122639073</phone>
      <email>elise.kelman@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

